The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
Open accessAbstract
The messenger RNA vaccine BNT162b2 (Pfizer–BioNTech) has 95% efficacy against coronavirus disease 2019 (Covid-19). Qatar launched a mass immunization campaign with this vaccine on December 21, 2020. As of March 31, 2021, a total of 385,853 persons had received at least one vaccine dose and 265,410 had completed the two doses. Vaccination scale-up occurred as Qatar was undergoing its second and third waves of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which were triggered by expansion of the B.1.1.7 variant (starting in mid-January 2021) and the B.1.351 variant (starting in mid-February 2021). The B.1.1.7 wave peaked during the first week of March, and the rapid expansion of B.1.351 started in mid-March and continues to the present day. Viral genome sequencing conducted from February 23 through March 18 indicated that 50.0% of cases of Covid-19 in Qatar were caused by B.1.351 and 44.5% were caused by B.1.1.7. Nearly all cases in which virus was sequenced after March 7 were caused by either B.1.351 or B.1.1.7.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Reduced protection against any symptomatic COVID-19 disease caused by the B.1.351 variant of concern (now known as the Beta variant) has been reported from clinical trials18, but emerging data suggest that there remains high protection against the important end points of severe disease and hospitalization99.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [99]
The cited source says what the claim attributes to it.
In the citing paper
“The test-negative design, which does not assume that a lack of a positive test equals a negative test and somewhat adjusts for testing volume, attempts to better mitigate this bias and is the reason we chose this method for this analysis”
From Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine (2022) · cites this paper as [25]
In the citing paper
“These inclusion and exclusion criteria were implemented to allow for build-up of immunity after vaccination4,14 and to minimize different types of potential bias, as informed by earlier analyses in the same population.”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [14]
In the citing paper
“Effectiveness was assessed with the use of an observational, test-negative, case–control design rather than a design in which cohorts of individual persons were followed up. However, the cohort study design applied earlier to the same population yielded findings similar to those of the test-negative design.14,15,31”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [14]
In the citing paper
“However, the cohort study design applied earlier to the same population of Qatar yielded findings similar to those of the test-negative case–control design36,38,39, supporting the validity of this standard approach in assessing vaccine effectiveness11,12,36,40.”
From Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar (2022) · cites this paper as [38]
In the citing paper
“As compared with recent findings from Qatar on the effectiveness of the BNT162b2 vaccine against the alpha and beta variants,17 our findings suggest that effectiveness against the delta variant after a full vaccination course lies somewhere between these two.”
From Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant (2021) · cites this paper as [17]
In the citing paper
“In cohort studies from Israel and Qatar, the BNT162b vaccine also retained greater than 90% efficacy against this variant 210,211 (TABLe 2).”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [211]
In the citing paper
“In the previously cited Qatar cohort study, the efficacy of BNT162b against the Beta variant was estimated to be 72%, which was 15% lower than that for the Alpha variant 211 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [211]
In the citing paper
“Likewise, clinical studies have reported somewhat reduced efficacy and effectiveness against the B.1.1.7, B.1.351, and B.1.617.2 variants (10–12).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [10]
In the citing paper
“The effectiveness of the BNT162b2 vaccine against the Beta variant was measured shortly after the population of Qatar had been vaccinated, whereas the effectiveness of BNT162b2 against the Delta variant was conducted several months after the second dose, which could be one of the reasons for low effectiveness of BNT162b2 against the Delta variant.404,405”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [405]
In the citing paper
“Beta [as a benchmark for partially reduced neutralization (7) without major impact on effectiveness (19, 20)]”
From Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera (2022) · cites this paper as [19]
In the citing paper
“Coronavirus disease 2019 (Covid-19) vaccines are highly effective against symptomatic disease and, more so, against severe disease and fatal outcomes caused by the original strain of SARS-CoV-2 as well as the alpha (B.1.1.7) variant that predominated in early 2021.”
From Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern (2021) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7013e3 · Cited by 707
The test-negative design for estimating influenza vaccine effectiveness
Jackson, M. L., & Nelson, J. C. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.053 · Cited by 510
Cited by
Sorted by citations
Items 301–400 of 879
Taus, E., Hofmann, C., Ibarrondo, F. J., Hausner, M. A., Fulcher, J. A., Krogstad, P. A., Ferbas, K. G., Tobin, N. H., Rimoin, A. W., Aldrovandi, G. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835830 · Cited by 31
Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents
Oliveira, C. R., Niccolai, L. M., Sheikha, H., Elmansy, L., Kalinich, C. C., Grubaugh, N. D., Shapiro, E. D., Initiative, Y. S.-C.-2. G. S., Billig, K., Breban, M. I., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.0935 · Cited by 31
Seki, Y., Yoshihara, Y., Nojima, K., Momose, H., Fukushi, S., Moriyama, S., Wagatsuma, A., Numata, N., Sasaki, K., Kuzuoka, T., et al. (2022) · Med · doi:10.1016/j.medj.2022.04.013 · Cited by 30
Wang, S., Sun, H., Zhang, Y., Yuan, L., Wang, Y., Zhang, T., Wang, S., Zhang, J., Yu, H. J., Xiong, H., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110862 · Cited by 30
Bello‐Chavolla, O. Y., Antonio‐Villa, N. E., Valdés‐Ferrer, S. I., Fermín‐Martínez, C. A., Fernández‐Chirino, L., Vargas‐Vázquez, A., Ramírez‐García, D., Mancilla-Galindo, J., Kammar‐García, A., Ávila‐Funes, J. A., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.01.040 · Cited by 32
History of primary-series and booster vaccination and protection against Omicron reinfection
Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Yassine, H. M., Thani, A. A. A., Al-Khatib, H. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh0761 · Cited by 30
Self-citationBeta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in France
Lefèvre, B., Tondeur, L., Madec, Y., Grant, R., Lina, B., van der Werf, S., Rabaud, C., Fontanet, A. L., & Legoff, A. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00230-0 · Cited by 29
Hafiz, I., Illian, D. N., Meila, O., Utomo, A. R. H., Susilowati, A., Susetya, I. E., Desrita, D., Siregar, G. A., & Basyuni, M. (2022) · Vaccines · doi:10.3390/vaccines10010082 · Cited by 31
Song, G., Yuan, M., Liu, H., Capozzola, T., Lin, R. N., Torres, J. L., He, W., Musharrafieh, R., Dueker, K., Zhou, P.-P., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115948 · Cited by 30
Mooij, P., García‐Arriaza, J., Pérez, P., Lázaro-Frías, A., Verstrepen, B. E., Böszörményi, K. P., Mortier, D., Fagrouch, Z. C., Kiemenyi-Kayere, G., Niphuis, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845887 · Cited by 29
Research progress on vaccine efficacy against SARS-CoV-2 variants of concern
Bian, L., Liu, J., Gao, F., Gao, Q., He, Q., Mao, Q., Wu, X., Xu, M., & Liang, Z. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2057161 · Cited by 30
Martellucci, C. A., Flacco, M. E., Soldato, G., Martino, G. D., Carota, R., Caponetti, A., & Manzoli, L. (2022) · Vaccines · doi:10.3390/vaccines10050662 · Cited by 29
El-Malah, S. S., Saththasivam, J., Jabbar, K. A., Arun, K. K., Gomez, T., Ahmed, A. A., Mohamoud, Y. A., Malek, J. A., Abu-Raddad, L. J., Halaweh, H. A. A., et al. (2022) · Environmental Technology & Innovation · doi:10.1016/j.eti.2022.102775 · Cited by 30
Self-citationChen, W., Zhang, L., Li, J., Bai, S., Wang, Y., Zhang, B., Zheng, Q., Chen, M., Zhao, W., & Wu, J. (2022) · Immunology · doi:10.1111/imm.13531 · Cited by 33
Ayoub, H. H., Tomy, M., Chemaitelly, H., Altarawneh, H. N., Coyle, P., Tang, P., Hasan, M. R., Kanaani, Z. A., Kuwari, E. A., Butt, A. A., et al. (2022) · doi:10.1101/2022.01.02.22268622 · Cited by 41
Self-citationDoherty, J., Fennessy, S., Stack, R., Morain, N. O., Cullen, G. J., Ryan, E. J., Gascun, C. F. D., & Doherty, G. A. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16590 · Cited by 29
Neumann, F., Rose, R., Römpke, J., Grobe, O., Lorentz, T., Fickenscher, H., & Krumbholz, A. (2021) · Vaccines · doi:10.3390/vaccines9070700 · Cited by 28
Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2
Castonguay, N., Zhang, W., & Langlois, M. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.676314 · Cited by 28
Haranaka, M., Baber, J., Ogama, Y., Yamaji, M., Aizawa, M., Kogawara, O., Scully, I. L., Lagkadinou, E., Türeci, Ö., Şahin, U., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27316-2 · Cited by 28
Kodera, S., Rashed, E. A., & Hirata, A. (2022) · Vaccines · doi:10.3390/vaccines10030430 · Cited by 28
Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
Günl, F., Mecate-Zambrano, A., Rehländer, S., Hinse, S., Ludwig, S., & Brunotte, L. (2021) · Vaccines · doi:10.3390/vaccines9101052 · Cited by 27
COVID-19 Vaccine Platforms: Challenges and Safety Contemplations
Al-Jighefee, H. T., Najjar, H., Ahmed, M. N., Qush, A., Awwad, S., & Kamareddine, L. (2021) · Vaccines · doi:10.3390/vaccines9101196 · Cited by 29
What Happens to the Immune System after Vaccination or Recovery from COVID-19?
Tiyo, B. T., Schmitz, G. J. H., Ortega, M. M., da Silva, L. T., de Almeida, A., Oshiro, T. M., & Duarte, A. J. D. S. (2021) · Life · doi:10.3390/life11111152 · Cited by 28
Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models
Sheward, D. J., Mandolesi, M., Urgard, E., Kim, C., Hanke, L., Vidakovics, L. P., Pankow, A. P., Smith, N. L., Dopico, X. C., McInerney, G. M., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100450 · Cited by 28
Müller, M. K., Volzke, J., Subin, B., Müller, S. C., Sombetzki, M., Reisinger, E. C., & Müller‐Hilke, B. (2022) · BMC Medicine · doi:10.1186/s12916-022-02240-4 · Cited by 27
A review of the safety and efficacy of current COVID-19 vaccines
Huang, Z., Su, Y., Zhang, T., & Xia, N. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0893-y · Cited by 28
Vaccine politics: Law and inequality in the pandemic response to COVID ‐19
Kavanagh, M. M., & Singh, R. (2023) · Global Policy · doi:10.1111/1758-5899.13203 · Cited by 27
The real-time infection hospitalisation and fatality risk across the COVID-19 pandemic in England
Ward, T., Fyles, M., Glaser, A., Paton, R. S., Ferguson, W., & Overton, C. E. (2024) · Nature Communications · doi:10.1038/s41467-024-47199-3 · Cited by 26
COVID-19: Malaysia's fight against this deadly virus
Loo, K.-Y., & Letchumanan, V. (2021) · Progress In Microbes & Molecular Biology · doi:10.36877/pmmb.a0000204 · Cited by 27
Nadesalingam, A., Cantoni, D. M., Wells, D. A., Aguinam, E. T., Ferrari, M., Smith, P., Chan, A., Carnell, G., Ohlendorf, L., Einhauser, S., et al. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00157-9 · Cited by 26
Rajpal, V. R., Sharma, S., Kumar, A., Chand, S., Joshi, L., Chandra, A., Babbar, S., Goel, S., Raina, S. N., & Shiran, B. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27749 · Cited by 26
Modelling the COVID-19 epidemic and the vaccination campaign in Italy by the SUIHTER model
Parolini, N., Dede’, L., Ardenghi, G., & Quarteroni, A. M. (2022) · Infectious Disease Modelling · doi:10.1016/j.idm.2022.03.002 · Cited by 29
Volkmann, A., Koopman, G., Mooij, P., Verschoor, E. J., Verstrepen, B. E., Bogers, W. M. J. M., Idorn, M., Paludan, S. R., Vang, S., Nielsen, M. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857440 · Cited by 27
Wang, R., Sun, C., Ma, J., Yu, C., Kong, D., Chen, M., Liu, X., Zhao, D., Gao, S., Kou, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10050702 · Cited by 26
Zhou, R., Liu, N., Li, X., Peng, Q., Yiu, C.-K., Huang, H., Yang, D., Du, Z., Kwok, H.-Y., Au, K.-K., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100660 · Cited by 26
Giuliano, A. R., Lancet, J. E., Pilon‐Thomas, S., Dong, N. C., Jain, A. G., Tan, E. S., Ball, S., Tworoger, S. S., Siegel, E. M., Whiting, J., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0001 · Cited by 25
COVID-19 Vaccination and Estimated Public Health Impact in California
Tan, S. T., Park, H. J., Rodríguez-Barraquer, I., Rutherford, G. W., Bibbins-Domingo, K. B., Schechter, R., & Lo, N. C. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.8526 · Cited by 26
Cobre, A. D. F., Surek, M., Stremel, D. P., Fachi, M. M., Borba, H. H. L., Tonin, F. S., & Pontarolo, R. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105659 · Cited by 25
Paternina-Caicedo, Á. J., Jit, M., Alvis‐Guzmán, N., Fernández, J. C., Hernández, J., Paz-Wilches, J., Rojas-Suárez, J. A., Castell, C. R. D., Alvis-Zakzuk, N. J., Smith, A. D., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100296 · Cited by 25
Active Safety Surveillance of Four Types of COVID-19 Vaccines: A National Study from Jordan
Abdel‐Qader, D. H., Abdel-Qader, H., Silverthorne, J., Kongkaew, C., Meslamani, A. Z. A., Hayajneh, W. A., Ata, O. A., Shnaigat, W., Aburuz, S., Nsour, M. A., et al. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01191-1 · Cited by 25
Considerations for Establishing Successful Coronavirus Disease Vaccination Programs in Africa
Williams, V., Edem, B. E., Calnan, M., Otwombe, K. N., & Okeahalam, C. C. (2021) · Emerging infectious diseases · doi:10.3201/eid2708.203870 · Cited by 24
Guzmán-Martínez, O., Guardado, K., de Guevara, E. L., Navarro, S. M., Hernández, C., Zenteno‐Cuevas, R., & Montero, H. (2021) · Vaccines · doi:10.3390/vaccines9090999 · Cited by 26
COVID-19 Vaccines: Current Conditions and Future Prospects
Zieneldien, T., Kim, J., Cao, J. A., & Cao, C. (2021) · Biology · doi:10.3390/biology10100960 · Cited by 24
Jodaylami, M. H., Djaïleb, A., Ricard, P., Lavallée, É., Cellier-Goetghebeur, S., Parker, M.-F., Coutu, J., Stuible, M., Gervais, C., Durocher, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00844-z · Cited by 28
Cheng, C.-J., Lu, C., Chang, Y., Sun, Y., Chu, H., Lee, C., Liu, C.-H., Lin, C.-H., Lu, C.-J., & Li, C. (2021) · Vaccines · doi:10.3390/vaccines9121489 · Cited by 24
Kister, I., Patskovsky, Y., Curtin, R., Pei, J., Perdomo, K., Rimler, Z., Voloshyna, I., Samanovic, M. I., Cornelius, A. R., Velmurugu, Y., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26346 · Cited by 24
Brinkkemper, M., Veth, T. S., Brouwer, P. J. M., Turner, H. L., Poniman, M., Burger, J. A., Bouhuijs, J. H., Olijhoek, W., Bontjer, I., Snitselaar, J. L., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105649 · Cited by 25
Research progress in spike mutations of SARS‐CoV‐2 variants and vaccine development
He, X., He, C., Hong, W., Yang, H. J., & Wei, X. (2023) · Medicinal Research Reviews · doi:10.1002/med.21941 · Cited by 25
COVID-19 vaccine strategies for Aotearoa New Zealand: a mathematical modelling study
Nguyen, T., Adnan, M., Nguyen, B. P., de Ligt, J., Geoghegan, J. L., Dean, R. A., Jefferies, S., Baker, M. G., Seah, W. K. G., Sporle, A. A., et al. (2021) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2021.100256 · Cited by 26
Babajani, A., Moeinabadi‐Bidgoli, K., Niknejad, F., Rismanchi, H., Shafiee, S., Shariatzadeh, S., Jamshidi, E., Farjoo, M. H., & Niknejad, H. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02794-3 · Cited by 24
Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial
Cromer, D., Reynaldi, A., Steain, M., Triccas, J. A., Davenport, M. P., & Khoury, D. S. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac075 · Cited by 23
Barghash, R. F., Gemmati, D., Awad, A. M., Elbakry, M. M. M., Tisato, V., Awad, K., & Singh, A. V. (2024) · Molecules · doi:10.3390/molecules29235564 · Cited by 24
Has SARS-CoV-2 reached peak fitness?
Burioni, R., & Topol, E. J. (2021) · Nature Medicine · doi:10.1038/s41591-021-01421-7 · Cited by 23
Molecular modeling of the interaction of ligands with ACE2–SARS-CoV-2 spike protein complex
Isaac-Lam, M. F. (2021) · In Silico Pharmacology · doi:10.1007/s40203-021-00114-w · Cited by 24
Al‐Sadeq, D. W., Shurrab, F. M., Ismail, A., Amanullah, F. H., Thomas, S., Al-Dewik, N. I. E., Yassine, H. M., Rahim, H. F. A., Abu-Raddad, L. J., & Nasrallah, G. K. (2021) · Journal of Travel Medicine · doi:10.1093/jtm/taab190 · Cited by 23
Self-citationThe need for linked genomic surveillance of SARS-CoV-2
Dushoff, C., Earn, D. J. D., Dushoff, J. G., Ogden, N. H., Li, M., Knox, N., Domselaar, G. V., Franklin, K., Jolly, G., & Otto, S. P. (2022) · Canada Communicable Disease Report · doi:10.14745/ccdr.v48i04a03 · Cited by 23
Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants
Li, C., Guo, Y., Fang, Z., Zhang, H., Zhang, Y., & Chen, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804945 · Cited by 23
Fukuda, H., Maeda, M., & Murata, F. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.059 · Cited by 23
Sacchi, M. C., Pelazza, C., Bertolotti, M., Agatea, L., Gaspari, P. D., Tamiazzo, S., Ielo, D., Stobbione, P., Grappiolo, M., Bolgeo, T., et al. (2023) · Autoimmunity · doi:10.1080/08916934.2023.2229072 · Cited by 23
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
Zhu, C., Pang, S., Liu, J., & Duan, Q. (2024) · Drugs · doi:10.1007/s40265-024-02013-8 · Cited by 24
SARS-CoV-2 variants of concern and vaccine escape, from Alpha to Omicron and beyond
Ong, S. W. X., Chia, T. R. T., & Young, B. E. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2057299 · Cited by 24
D’Amelio, R., Asero, R., Cassatella, M. A., Laganà, B., Lunardi, C., Migliorini, P., Nisini, R., Parronchi, P., Quinti, I., Racanelli, V., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091163 · Cited by 22
Pani, A., Cento, V., Vismara, C., Campisi, D., Ruscio, F. D., Romandini, A., Senatore, M., Schenardi, P. A., Gagliardi, O. M., Giroldi, S., et al. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.08.013 · Cited by 22
Dick, D. W., Childs, L. M., Feng, Z., Li, J., Röst, G., Buckeridge, D. L., Ogden, N. H., & Heffernan, J. M. (2021) · Vaccines · doi:10.3390/vaccines10010017 · Cited by 23
Counoupas, C., Pino, P., Stella, A. O., Ashley, C. L., Lukeman, H., Bhattacharyya, N. D., Tada, T., Anchisi, S., Metayer, C., Martinis, J., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01695-21 · Cited by 22
Li, X., Wang, L., Liu, J., Fang, E., Liu, X., Peng, Q., Zhang, Z., Li, M., Liu, X., Wu, X., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2097479 · Cited by 22
Li, Y. E., Wang, S., Reiter, R. J., & Ren, J. T. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.08.026 · Cited by 23
Ma, S., Damfo, S. A., Lou, J., Pinotsis, N., Bowler, M. W., Haider, S. M., & Kozielski, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012448 · Cited by 22
Fiolet, T., Kherabi, Y., MacDonald, C. J., Ghosn, J., & Peiffer‐Smadja, N. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/z4x7t · Cited by 22
Peng, L., Renauer, P. A., Ökten, A., Fang, Z., Park, J. J., Zhou, X., Lin, Q., Dong, M. B., Filler, R., Xiong, Q., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100634 · Cited by 21
Baum, U., Poukka, E., PALMU, A. A. I., Salo, H., Lehtonen, T., & Leino, T. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258704 · Cited by 21
Baltas, I., Boshier, F. A. T., Williams, C. A., Bayzid, N., Cotic, M., Guerra‐Assunção, J. A., Irish, D. N., Haque, T., Hart, J., Roy, S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab714 · Cited by 22
Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines
Zhang, Y., Ndzouboukou, J. B., Gan, M., Lin, X., & Fan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.771242 · Cited by 21
Decoupling of omicron variant infections and severe COVID-19
Madhi, S. A., Ihekweazu, C., Rees, H., & Pollard, A. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00109-x · Cited by 21
The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA
Taina-González, L., & de la Fuente, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020460 · Cited by 23
van der Velden, Y. U., Grobben, M., Caniels, T. G., Burger, J. A., Poniman, M., Oomen, M., Rijnstra, E. S.-V., Tejjani, K., Guerra, D., Kempers, R., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07590-w · Cited by 21
Classifying COVID-19 Variants Based on Genetic Sequences Using Deep Learning Models
Basu, S., & Campbell, R. H. (2022) · Springer series in reliability engineering · doi:10.1007/978-3-031-02063-6_19 · Cited by 22
Khawaja, F., Papanicolaou, G. A., Dadwal, S., Pergam, S. A., Wingard, J. R., Boghdadly, Z. E., Abidi, M. Z., Waghmare, A., Shahid, Z., Michaels, L., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.10.010 · Cited by 21
Modeling the Impact of COVID-19 Vaccination in Lebanon: A Call to Speed-Up Vaccine Roll Out
Mumtaz, G. R., El‐Jardali, F., Jabbour, M., Harb, A., Abu-Raddad, L. J., & Makhoul, M. (2021) · Vaccines · doi:10.3390/vaccines9070697 · Cited by 23
Self-citationImai, N., Hogan, A. B., Williams, L. R., Cori, A., Mangal, T. D., Winskill, P., Whittles, L. K., Watson, O. J., Knock, E., Baguelin, M., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16992.1 · Cited by 21
Chowdhury, A., Sajid, M., Jahan, N., Adelusi, T. I., Maitra, P., Yin, G., Wu, X., Gao, Y., & Wang, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111956 · Cited by 21
Reinfections in COVID-19 Patients: Impact of Virus Genetic Variability and Host Immunity
Fakhroo, A. D., Al-Khatib, H. A., Thani, A. A. A., & Yassine, H. M. (2021) · Vaccines · doi:10.3390/vaccines9101168 · Cited by 21
Butt, A. A., Talisa, V. B., Peng, Y., Shaikh, O. S., Omer, S. B., & Mayr, F. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac178 · Cited by 20
Self-citationLee, V. H.-F., Adham, M., Kridis, W. B., Bossi, P., Chen, M., Chitapanarux, I., Grégoire, V., Hao, S. P., Ho, C., Ho, G. F., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00505-8 · Cited by 21
Heidarzadeh, A., Moridani, M. A., Khoshmanesh, S., Kazemi, S., Hajiaghabozorgi, M., & Karami, M. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.12.024 · Cited by 20
Tsang, T. K., Sullivan, S. G., Huang, X., Wang, C., Wang, Y., Nealon, J., Yang, B., Ainslie, K. E. C., & Cowling, B. J. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae142 · Cited by 21
Possible Targets of Pan-Coronavirus Antiviral Strategies for Emerging or Re-Emerging Coronaviruses
Li, X., Zhang, L., Chen, S. E., Ouyang, H., & Ren, L. (2021) · Microorganisms · doi:10.3390/microorganisms9071479 · Cited by 20
Ghosh, D., Dastidar, D. G., Roy, K., Ghosh, A., Mukhopadhyay, D., Sikdar, N., Biswas, N. K., Chakrabarti, G., & Das, A. K. (2022) · Scientific Reports · doi:10.1038/s41598-022-09845-y · Cited by 20
Antibody-mediated immunity to SARS-CoV-2 spike
Errico, J. M., Adams, L. J., & Fremont, D. H. (2022) · Advances in immunology · doi:10.1016/bs.ai.2022.07.001 · Cited by 22
Wu, T., Kang, S., Peng, W., Zuo, C., Zhu, Y., Pan, L., Fu, K., You, Y., Yang, X., Luo, X., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.702066 · Cited by 21
Optimizing testing regimes for the detection of COVID-19 in children and older adults
Chauhan, N., Soni, S., & Jain, U. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1962708 · Cited by 19
RETRACTED: Deep Fractional Max Pooling Neural Network for COVID-19 Recognition
Wang, S., Satapathy, S. C., Anderson, D., Chen, S.-X., & Zhang, Y. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.726144 · Cited by 19
RetractedWang, B., Goh, Y. S., Prince, T., Ngoh, E. Z. X., Salleh, S. N. M., Hor, P. X., Loh, C. Y., Fong, S., Hartley, C. S., Tan, S. Y., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00389-2 · Cited by 19
Katz, M. A., Bron‐Harlev, E., Chazan, B., Chowers, M., Greenberg, D., Peretz, A., Tshori, S., Levy, J., Yacobi, M., Hirsch, A., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.11.092 · Cited by 19
The Effectiveness of COVID-19 Vaccines in Improving the Outcomes of Hospitalized COVID-19 Patients
Alsaffar, W. A., Alwesaibi, A. A., Alhaddad, M. J., Alsenan, Z. K., Alsheef, H. J., AlRamadan, S., Aljassas, H. A., Alsaghirat, M. A., & Alzahrani, H. J. (2022) · Cureus · doi:10.7759/cureus.21485 · Cited by 19
Critical policies disparity of the first and second waves of COVID-19 in the United Kingdom
Yang, M., Shi, L., Chen, H., Wang, X., Jiao, J., Liu, M., Yang, J., & Sun, G. (2022) · International Journal for Equity in Health · doi:10.1186/s12939-022-01723-3 · Cited by 19
Mouse models of lung-specific SARS-CoV-2 infection with moderate pathological traits
Kim, S., Kim, J., Jang, J. Y., Noh, H., Park, J., Jeong, H., Jeon, D., Uhm, C., Oh, H., Cho, K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1055811 · Cited by 19
Wiedermann, M., Rose, A. H., Maier, B. F., Kolb, J. J., Hinrichs, D., & Brockmann, D. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad223 · Cited by 21
Picazo, J. J. (2021) · Revista Española de Quimioterapia · doi:10.37201/req/085.2021 · Cited by 22
Cognitive Barriers to COVID-19 Vaccine Uptake Among Older Adults
Chia, J. L., & Hartanto, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.756275 · Cited by 19
Metadata
- Authors
- Abu-Raddad, L. J., Chemaitelly, H., & Butt, A. A.
- Affiliations
- Weill Cornell Medical College in Qatar (QA)
- Hamad Medical Corporation (QA)
- Corresponding author
- Abu-Raddad, Laith J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-07-08
- Volume
- 385
- Issue
- 2
- Pages
- 187-189
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8117967
- OpenAlex
- W3157162195
- Cited by
- 899
- References
- 4
- Citations by year
- 2026: 16 · 2025: 32 · 2024: 46 · 2023: 92 · 2022: 358 · 2021: 351
- FWCI
- 67.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Qatar University QSpace (Qatar University) (submittedVersion)
- Funders
- Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, the Ministry of Public Health and Hamad Medical Corporation
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- BNT162b2, COVID-19 vaccine efficacy, SARS-CoV-2 variants, B.1.1.7 variant, B.1.351 variant, Omicron variant, vaccination campaigns, viral genome sequencing, COVID-19 waves
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Humans, Qatar, Cohort Studies, Case-Control Studies, Polymerase Chain Reaction, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
